Cambridge-based liquid biopsy startup Mursla Bio has secured a US Food and Drug Administration (FDA) breakthrough device designation for its lead product, EvoLiver.
The blood-based liquid biopsy test uses extracellular vesicles (EVs) to detect hepatocellular carcinoma (HCC), the most common form of primary liver cancer in high-risk cirrhotic patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?